Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Prolonged tioguanine therapy for IBD well tolerated, effective in maintenance setting

15 Jul 2019

Use of tioguanine for at least 12 months appears to be effective in the maintenance treatment of inflammatory bowel disease (IBD), and while adverse events are common, most are clinically tolerable, according to a recent study.

The study population comprised 274 tioguanine-treated IBD patients (median age at tioguanine initiation, 43 years; 63 percent female; 68 percent had Crohn’s disease). Median duration of treatment was 51 months, with median tioguanine dosage being 20 mg/d. There were 1,567 patient-years of follow-up.

Clinical effectiveness (defined as treatment response without [re]initiation of corticosteroids, concurrent biological therapy or surgical intervention) at 6 months was documented in 66 percent of patients, while sustained clinical effectiveness for 12 months was reported in 51 percent. Treatment was tolerable in most patients (79 percent).

Adverse events occurred in 41 percent of patients, including 5 percent who developed events graded as severe. Three patients had infection requiring hospitalization, while eight had skin cancer (two melanomas). Asymptomatic nodular regenerative hyperplasia of the liver occurred in two out of 52 patients with liver biopsies, and portal hypertension was recorded in three, including one case potentially associated with tioguanine.

Clinical effectiveness correlated with 6‐thioguanine nucleotide threshold concentrations >682 pmol/8×10RBC (p<0.05).

In light of the findings, researchers stressed that the therapeutic benefit of tioguanine needs to be balanced with associated toxicity when considering a role for this thiopurine‐derivative in IBD treatment. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.